Amarin Corporation plc(AMRN)Earnings, Financials & Key Ratios

AMRN•NASDAQ

$15.46

Price updated Jul 7, 2026

SectorHealthcare IndustryBiotechnology Sub-IndustryCommercial Specialty Pharma

AboutAmarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. The company sells its products principally to wholesalers and specialty pharmacy providers. It has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa, the omega-3 acid, and eicosapentaenoic acid. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Show more

Revenue$214M-6.5%
EBITDA-$11M+87.7%
Net Income-$39M+52.8%
EPS (Diluted)-1.80+55.0%
Gross Margin56.57%+58.9%
EBITDA Margin-5.11%+86.8%
Operating Margin-6.53%+83.7%
Net Margin-18.16%+49.5%
ROE-8.21%+48.2%

AMRN Price & Volume

Amarin Corporation plc (AMRN) stock price & volume — 10-year historical chart

Loading chart...

Persistent Revenue Erosion Challenges Amarin Financial Stability

Investment Thesis • Updated 2026Q1

VerdictNegative

Growth:Contracting

Profitability:Negative

Financial:Vulnerable

Cash Flow:Mixed

Primary Risk:Single product revenue erosion

Key Thesis Takeaways

Amarin faces a precarious outlook as it struggles to mitigate the impact of U.S.
generic competition on its core cardiovascular franchise.
While the company maintains a current ratio of 3.48, the persistent net losses and an accumulated deficit of $1.7 billion raise significant concerns regarding long-term solvency.
Investors should monitor the company's ability to stabilize gross margins, which have compressed to 41.0% in 2026Q1, as the firm attempts to pivot its commercial strategy amidst ongoing operational cash burn.

Verdict Logic

the company's inability to achieve consistent profitability, evidenced by a $10.5 million net loss in 2026Q1, suggests that the current cash runway may be insufficient to support long-term commercialization without further dilution.

AMRN Growth Metrics

Amarin Corporation plc (AMRN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years10.08%

5 Years-19.04%

3 Years-16.67%

TTM0.33%

Profit CAGR

10 Years-

5 Years-

3 Years-

TTM61.77%

EPS CAGR

10 Years-

5 Years-

3 Years-

TTM62.14%

Return on Capital

10 Years-25.59%

5 Years-9.12%

3 Years-10.38%

Last Year-2.84%

AMRN Recent Earnings

Amarin Corporation plc (AMRN) EPS & revenue vs analyst estimates — last 4 quarters

Full history →

●Beat EPS 5/12 qtrs (42%)●Beat Revenue 9/12 qtrs (75%)

Q2 2026Latest

Apr 29, 2026

Metric

Actual

Est

EPS

$0.09-1000.0%

$0.01

Rev

$45M+3.1%

$44M

Q1 2026

Feb 25, 2026

Metric

Actual

Est

EPS

$0.01-85.7%

$0.07

Rev

$49M-2.8%

$51M

Q4 2025

Oct 29, 2025

Metric

Actual

Est

EPS

$0.01-87.5%

$0.08

Rev

$49M-4.1%

$51M

Q3 2025

Jul 30, 2025

Metric

Actual

Est

EPS

$0.03+95.5%

$0.66

Rev

$47M+10.9%

$42M

Quarter	Date	EPS (Act vs Est)	Revenue (Act vs Est)
Q2 2026Latest	Apr 29, 2026	$0.09vs $0.01-1000.0%	$45Mvs $44M+3.1%
Q1 2026	Feb 25, 2026	$0.01vs $0.07-85.7%	$49Mvs $51M-2.8%
Q4 2025	Oct 29, 2025	$0.01vs $0.08-87.5%	$49Mvs $51M-4.1%
Q3 2025	Jul 30, 2025	$0.03vs $0.66+95.5%	$47Mvs $42M+10.9%

Based on last 12 quarters of dataView full earnings history →

Latest AMRN News

Recent stock market news and headlines for Amarin Corporation plc (AMRN)

GlobeNewsWire·Jun 30, 2026

Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape

Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides Clinically Validated, Increasingly Prescribed, Widely Reimbursed, and Affordable, VASCEPA Expected to Benefit from Increased Attention to Patients with Severely Elevated Triglycerides

Peers Comparison

Key metrics vs top competitors for Amarin Corporation plc (AMRN)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
AMRNAmarin Corporation plcCurrent	$15.46	$321.57M	-8.59	-6.55%	-18.16%	-8.21%	—
ELANElanco Animal Health Incorporated	$24.64	$12.31B	-52.43	6.22%	-4.95%	-3.64%	—
ACADACADIA Pharmaceuticals Inc.	$26.20	$4.49B	11.44	11.87%	34.3%	35.65%	—
SUPNSupernus Pharmaceuticals, Inc.	$47.41	$2.73B	-69.72	8.63%	-3.74%	-2.73%	—
HRMYHarmony Biosciences Holdings, Inc.	$38.26	$2.21B	14.12	21.51%	16.2%	17.19%	—
PRGOPerrigo Company plc	$11.19	$1.55B	-1.09	-2.75%	-43.5%	-50.65%	—

Compare AMRN vs Peers

Amarin Corporation plc (AMRN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs ELAN

Most directly comparable listed peer for AMRN.

Scale Benchmark

vs ABBV

Larger-name benchmark to compare AMRN against a more recognizable public peer.

Peer Set

Compare Top 5

vs ELAN, ACAD, SUPN, HRMY

AMRN SEC Filings & Documents

Amarin Corporation plc (AMRN) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Apr 29, 2026·SEC

Material company update

Mar 27, 2026·SEC

Material company update

Feb 25, 2026·SEC

10-K Annual Reports

FY 2026

Mar 2, 2026·SEC

FY 2025

Mar 12, 2025·SEC

FY 2024

Feb 29, 2024·SEC

10-Q Quarterly Reports

FY 2026

Apr 29, 2026·SEC

FY 2025

Oct 29, 2025·SEC

FY 2025

Jul 30, 2025·SEC

Get notified when AMRN posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

AMRN Frequently Asked Questions

Amarin Corporation plc (AMRN) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

What is Amarin Corporation plc's revenue?

Amarin Corporation plc (AMRN) reported $214.9M in revenue for fiscal year 2025. This represents a 899% increase from $21.5M in 1996.

How fast is Amarin Corporation plc growing?

Amarin Corporation plc (AMRN) saw revenue decline by 6.5% over the past year.

Is AMRN profitable?

Amarin Corporation plc (AMRN) reported a net loss of $33.6M for fiscal year 2025.

Dividend & Returns

What is AMRN's return on equity?

Amarin Corporation plc (AMRN) has a return on equity (ROE) of -8.2%. Negative ROE indicates the company is unprofitable.

What is Amarin Corporation plc's free cash flow?

Amarin Corporation plc (AMRN) generated $25.5M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

What if you invested $1,000 in AMRN back in 1996?

Total return calculator · dividends reinvested · 30+ years of data

See returns →

Quarter

Date

EPS (Act vs Est)

Revenue (Act vs Est)

Q2 2026Latest

Apr 29, 2026

$0.09vs $0.01-1000.0%

$45Mvs $44M+3.1%

Q1 2026

Feb 25, 2026

$0.01vs $0.07-85.7%

$49Mvs $51M-2.8%

Q4 2025

Oct 29, 2025

$0.01vs $0.08-87.5%

$49Mvs $51M-4.1%

Q3 2025

Jul 30, 2025

$0.03vs $0.66+95.5%

$47Mvs $42M+10.9%

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

AMRNAmarin Corporation plcCurrent

$15.46

$321.57M

-8.59

-6.55%

-18.16%

-8.21%

—

ELANElanco Animal Health Incorporated

$24.64

$12.31B

-52.43

6.22%

-4.95%

-3.64%

—

ACADACADIA Pharmaceuticals Inc.

$26.20

$4.49B

11.44

11.87%

34.3%

35.65%

—

SUPNSupernus Pharmaceuticals, Inc.

$47.41

$2.73B

-69.72

8.63%

-3.74%

-2.73%

—

HRMYHarmony Biosciences Holdings, Inc.

$38.26

$2.21B

14.12

21.51%

16.2%

17.19%

—

PRGOPerrigo Company plc

$11.19

$1.55B

-1.09

-2.75%

-43.5%

-50.65%

—